Skip to main content

RAS: Past, Present, and Future

  • 1st Edition, Volume 153 - January 29, 2022
  • Editors: John P. O'Bryan, Gary Piazza
  • Language: English
  • Hardback ISBN:
    9 7 8 - 0 - 1 2 - 8 2 4 4 8 5 - 2
  • eBook ISBN:
    9 7 8 - 0 - 1 2 - 8 2 4 4 8 6 - 9

Advances in Cancer Research, volume 153 provides a timely review of the biology, biochemistry, and current approaches to therapeutically target the RAS oncoprotein, the most freque… Read more

RAS: Past, Present, and Future

Purchase options

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code needed.

Image of books

Institutional subscription on ScienceDirect

Request a sales quote
Advances in Cancer Research, volume 153 provides a timely review of the biology, biochemistry, and current approaches to therapeutically target the RAS oncoprotein, the most frequently mutated oncogene family in human cancers. 2021 saw the approval of the first direct RAS inhibitor (sotorasib) for use in treating non-small cell lung cancers harboring KRAS(G12C) mutations. The successful approval and use of this drug highlights that the once “undruggable” RAS is indeed pharmacologically tractable. This volume provides an overview of efforts to develop additional approaches to therapeutically target oncogenic RAS. In addition, the reader will find excellent reviews on the history and research efforts to understand the biochemistry and oncogenic activity of RAS in human cancers.